Taking the current outcomes of the clinical trials of the p53-targeting therapies, it can be concluded that the management of the TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) remains a therapeutic challenge despite significant recent advancements. Here, TP53 is linked to myelodysplastic syndrome.